Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Clin Cancer Res
2009 Oct 01;1519:6062-9. doi: 10.1158/1078-0432.CCR-09-0048.
Show Gene links
Show Anatomy links
Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters.
Hu S
,
Chen Z
,
Franke R
,
Orwick S
,
Zhao M
,
Rudek MA
,
Sparreboom A
,
Baker SD
.
???displayArticle.abstract???
PURPOSE: To compare side-by-side the uptake of sorafenib and sunitinib in vitro by human uptake solute carriers of the SLC22A and SLCO families, the transport by and inhibition of efflux ATP-binding cassette (ABC) transporters, and the role of ABCB1 in the plasma pharmacokinetics and brain penetration of these agents.
EXPERIMENTAL DESIGN: Uptake of [(3)H]sorafenib or [(3)H]sunitinib was assessed in Xenopus laevis oocytes or mammalian cells transfected with cDNAs coding for human OATP1A2, OATP1B1, OATP1B3, OCT1, OAT2, OAT3, OCTN1, or OCTN2. Efflux and inhibition experiments were conducted in cells transfected with human ABCB1, ABCG2, ABCC2, or ABCC4. In vivo pharmacokinetic studies were done in knockout mice lacking Abcb1-type transporters.
RESULTS: Intracellular uptake was not appreciably affected by any of the studied solute carriers and was minute relative to the respective prototypical substrates. Sorafenib and sunitinib showed concentration-dependent (1 and 10 micromol/L), low to moderate affinity for ABCB1 but were not affected by the other ABC transporters. Both agents inhibited all tested ABC transporters. The absence of Abcb1 had no affect on plasma pharmacokinetics, but brain penetration was moderately increased by 1.9- and 2.9-fold for sorafenib and sunitinib, respectively, in knockout animals versus controls.
CONCLUSIONS: Unlike other tyrosine kinase inhibitors, sorafenib and sunitinib do not appear to rely on active transport to enter the cell nor are they high-affinity substrates for ABC efflux transporters. Based on these characteristics, these two drugs may be less susceptible to transporter-mediated alterations in systemic exposure and transporter-related resistance mechanisms.
Ambudkar,
Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells.
1998, Pubmed
Ambudkar,
Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells.
1998,
Pubmed
Baker,
Pharmacogenetic pathway analysis of docetaxel elimination.
2009,
Pubmed
,
Xenbase
Baker,
Pharmacokinetic considerations for new targeted therapies.
2009,
Pubmed
Bardelmeijer,
Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir.
2002,
Pubmed
Breedveld,
The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.
2005,
Pubmed
Brendel,
Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.
2007,
Pubmed
Burger,
Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.
2004,
Pubmed
Chow,
Sunitinib: from rational design to clinical efficacy.
2007,
Pubmed
Dai,
Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
2008,
Pubmed
Fabian,
A small molecule-kinase interaction map for clinical kinase inhibitors.
2005,
Pubmed
Franke,
Influence of solute carriers on the pharmacokinetics of CYP3A4 probes.
2008,
Pubmed
Grube,
Uptake of cardiovascular drugs into the human heart: expression, regulation, and function of the carnitine transporter OCTN2 (SLC22A5).
2006,
Pubmed
Hakimé,
Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice.
2007,
Pubmed
Hiwase,
Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications.
2008,
Pubmed
Houghton,
Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.
2004,
Pubmed
Hu,
Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia.
2008,
Pubmed
Hu,
Interaction of imatinib with human organic ion carriers.
2008,
Pubmed
,
Xenbase
Huang,
Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance.
2004,
Pubmed
Leis,
Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571).
2004,
Pubmed
Lenihan,
Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?
2008,
Pubmed
Li,
Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.
2007,
Pubmed
Mann,
Targeted cancer therapeutics: the heartbreak of success.
2006,
Pubmed
Marchetti,
Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.
2008,
Pubmed
Medioni,
Complete cerebral response with sunitinib for metastatic renal cell carcinoma.
2007,
Pubmed
Minkin,
Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry.
2008,
Pubmed
Mori,
Potential role of sorafenib in the treatment of acute myeloid leukemia.
2008,
Pubmed
Nakamura,
Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
2005,
Pubmed
Nezu,
Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter.
1999,
Pubmed
Okabe,
Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters.
2008,
Pubmed
Oostendorp,
The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib.
2009,
Pubmed
Petzer,
Low concentrations of STI571 in the cerebrospinal fluid: a case report.
2002,
Pubmed
Porkka,
Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia.
2008,
Pubmed
Shi,
Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
2007,
Pubmed
Shukla,
Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.
2009,
Pubmed
Szakács,
Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells.
2004,
Pubmed
Tahara,
Inhibition of oat3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid.
2006,
Pubmed
Takayama,
Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid.
2002,
Pubmed
Takimoto,
Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials.
2008,
Pubmed
Thomas,
Active transport of imatinib into and out of cells: implications for drug resistance.
2004,
Pubmed
Valcamonico,
Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma.
2009,
Pubmed
Vlaming,
Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice.
2006,
Pubmed
White,
OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib.
2006,
Pubmed
Wierdl,
Carboxylesterase-mediated sensitization of human tumor cells to CPT-11 cannot override ABCG2-mediated drug resistance.
2003,
Pubmed
Wilhelm,
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.
2006,
Pubmed
Yang,
Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein.
2005,
Pubmed
Zhang,
Organic cation transporters are determinants of oxaliplatin cytotoxicity.
2006,
Pubmed
Zhang,
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
2008,
Pubmed
Zhao,
A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay.
2007,
Pubmed
Zimmermann,
Species-dependent transport and modulation properties of human and mouse multidrug resistance protein 2 (MRP2/Mrp2, ABCC2/Abcc2).
2008,
Pubmed
van Herwaarden,
Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism.
2007,
Pubmed
